NOT-CA-26-012: Notice to Extend the Expiration Date for PAR-25-096 "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)"

Notice to Extend the Expiration Date for PAR-25-096 "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)"

Notice Number:

NOT-CA-26-012

Key Dates

Release Date:

May 28, 2026

Related Announcements

November 18, 2024 - Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed). See PAR-25-096

Issued by

National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to extend the expiration date for PAR-25-096, "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trial Not Allowed)".

Therefore, with the addition/extension by one Application Due Date, PAR-25-096 now expires on November 17, 2026.

The following sections in Part 1. Overview Information, Key Dates section have been changed:

Currently reads and modified to read (in bold italics):

New	Renewal/ Resubmission/ Revision	AIDS	Scientific Merit Review	Advisory Council Review	Earliest Start Date
February 16, 2025	March 16, 2025	Not Applicable	July 2025	October 2025	December 2025
June 16, 2025	July 16, 2025	Not Applicable	November 2025	January 2026	April 2026
October 16, 2025	November 16, 2025	Not Applicable	March 2026	May 2026	July 2026
February 16, 2026	March 16, 2026	Not Applicable	July 2026	October 2026	December 2026
June 16, 2026	July 16, 2026	Not Applicable	November 2026	January 2027	April 2027
October 16, 2026	November 16, 2026	Not Applicable	March 2027	May 2027	July 2027

Currently reads:

Expiration Date: September 08, 2026

Modified to read (in italics):

Expiration Date: November 17, 2026

All other aspects of PAR-25-096 remain unchanged.

Inquiries

Please direct all inquiries to:

Email: [email protected]